Loading
Led the first-in-human trial of BCMA CAR-T (bb2121) in myeloma and studies of bone disease treatment.
Noopur Raje led the first-in-human trial of bb2121 (idecabtagene vicleucel), which showed deep responses in heavily pretreated myeloma and launched BCMA-directed CAR-T therapy, and the trial establishing denosumab as an alternative to zoledronic acid for myeloma bone disease. She directs the myeloma centre at MGH and leads trials of bispecifics and next-generation cell therapies.
Shares KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma, BCMA, CAR-T cell therapy, Multiple myeloma and the tags myeloma, car-t.
Shares BCMA, CAR-T cell therapy, Multiple myeloma and the tags myeloma, car-t.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
Shares Massachusetts General Hospital Cancer Center, CAR-T cell therapy and the tag car-t.
Shares BCMA, Multiple myeloma.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.